A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NEW ENGLAND JOURNAL OF MEDICINE 2020-05, Vol.382 (22), p.2117-2128
Hauptverfasser: Kelly, Aaron S, Auerbach, Pernille, Barrientos-Perez, Margarita, Gies, Inge, Hale, Paula M, Marcus, Claude, Mastrandrea, Lucy D, Prabhu, Nandana, Arslanian, Silva
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2128
container_issue 22
container_start_page 2117
container_title NEW ENGLAND JOURNAL OF MEDICINE
container_volume 382
creator Kelly, Aaron S
Auerbach, Pernille
Barrientos-Perez, Margarita
Gies, Inge
Hale, Paula M
Marcus, Claude
Mastrandrea, Lucy D
Prabhu, Nandana
Arslanian, Silva
description BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to
format Article
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_20_500_12942_755274</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20_500_12942_755274</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_20_500_12942_7552743</originalsourceid><addsrcrecordid>eNqVjL0KwjAYADMoWKvv8M1iJU1basdSFBFBkO4hNl81GhtpUv-eXgcfQG-55bge8Shl8yBOs2hAhtae6IcwzjyyzmEnGmku6oVyCoVpXGu0Rgllq4QGU8NGteKgO6ckQm1ayKXRaCtsnIW7ckfY7tEq9xyRfi20xfHXPpksF2WxCs6dxu6GDZf2KirkjPKEUh6yLGY8TRKWxpFPZj_H3D1c9Nf9DbvuTQk</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity</title><source>Lirias (KU Leuven Association)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Kelly, Aaron S ; Auerbach, Pernille ; Barrientos-Perez, Margarita ; Gies, Inge ; Hale, Paula M ; Marcus, Claude ; Mastrandrea, Lucy D ; Prabhu, Nandana ; Arslanian, Silva</creator><creatorcontrib>Kelly, Aaron S ; Auerbach, Pernille ; Barrientos-Perez, Margarita ; Gies, Inge ; Hale, Paula M ; Marcus, Claude ; Mastrandrea, Lucy D ; Prabhu, Nandana ; Arslanian, Silva</creatorcontrib><description>BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to &lt;18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).</description><identifier>ISSN: 0028-4793</identifier><language>eng</language><publisher>MASSACHUSETTS MEDICAL SOC</publisher><ispartof>NEW ENGLAND JOURNAL OF MEDICINE, 2020-05, Vol.382 (22), p.2117-2128</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,777,781,27841</link.rule.ids></links><search><creatorcontrib>Kelly, Aaron S</creatorcontrib><creatorcontrib>Auerbach, Pernille</creatorcontrib><creatorcontrib>Barrientos-Perez, Margarita</creatorcontrib><creatorcontrib>Gies, Inge</creatorcontrib><creatorcontrib>Hale, Paula M</creatorcontrib><creatorcontrib>Marcus, Claude</creatorcontrib><creatorcontrib>Mastrandrea, Lucy D</creatorcontrib><creatorcontrib>Prabhu, Nandana</creatorcontrib><creatorcontrib>Arslanian, Silva</creatorcontrib><title>A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity</title><title>NEW ENGLAND JOURNAL OF MEDICINE</title><description>BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to &lt;18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).</description><issn>0028-4793</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVjL0KwjAYADMoWKvv8M1iJU1basdSFBFBkO4hNl81GhtpUv-eXgcfQG-55bge8Shl8yBOs2hAhtae6IcwzjyyzmEnGmku6oVyCoVpXGu0Rgllq4QGU8NGteKgO6ckQm1ayKXRaCtsnIW7ckfY7tEq9xyRfi20xfHXPpksF2WxCs6dxu6GDZf2KirkjPKEUh6yLGY8TRKWxpFPZj_H3D1c9Nf9DbvuTQk</recordid><startdate>20200528</startdate><enddate>20200528</enddate><creator>Kelly, Aaron S</creator><creator>Auerbach, Pernille</creator><creator>Barrientos-Perez, Margarita</creator><creator>Gies, Inge</creator><creator>Hale, Paula M</creator><creator>Marcus, Claude</creator><creator>Mastrandrea, Lucy D</creator><creator>Prabhu, Nandana</creator><creator>Arslanian, Silva</creator><general>MASSACHUSETTS MEDICAL SOC</general><scope>FZOIL</scope></search><sort><creationdate>20200528</creationdate><title>A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity</title><author>Kelly, Aaron S ; Auerbach, Pernille ; Barrientos-Perez, Margarita ; Gies, Inge ; Hale, Paula M ; Marcus, Claude ; Mastrandrea, Lucy D ; Prabhu, Nandana ; Arslanian, Silva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_20_500_12942_7552743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kelly, Aaron S</creatorcontrib><creatorcontrib>Auerbach, Pernille</creatorcontrib><creatorcontrib>Barrientos-Perez, Margarita</creatorcontrib><creatorcontrib>Gies, Inge</creatorcontrib><creatorcontrib>Hale, Paula M</creatorcontrib><creatorcontrib>Marcus, Claude</creatorcontrib><creatorcontrib>Mastrandrea, Lucy D</creatorcontrib><creatorcontrib>Prabhu, Nandana</creatorcontrib><creatorcontrib>Arslanian, Silva</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>NEW ENGLAND JOURNAL OF MEDICINE</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kelly, Aaron S</au><au>Auerbach, Pernille</au><au>Barrientos-Perez, Margarita</au><au>Gies, Inge</au><au>Hale, Paula M</au><au>Marcus, Claude</au><au>Mastrandrea, Lucy D</au><au>Prabhu, Nandana</au><au>Arslanian, Silva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity</atitle><jtitle>NEW ENGLAND JOURNAL OF MEDICINE</jtitle><date>2020-05-28</date><risdate>2020</risdate><volume>382</volume><issue>22</issue><spage>2117</spage><epage>2128</epage><pages>2117-2128</pages><issn>0028-4793</issn><abstract>BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to &lt;18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).</abstract><pub>MASSACHUSETTS MEDICAL SOC</pub></addata></record>
fulltext fulltext
identifier ISSN: 0028-4793
ispartof NEW ENGLAND JOURNAL OF MEDICINE, 2020-05, Vol.382 (22), p.2117-2128
issn 0028-4793
language eng
recordid cdi_kuleuven_dspace_20_500_12942_755274
source Lirias (KU Leuven Association); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine
title A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A56%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Randomized,%20Controlled%20Trial%20of%20Liraglutide%20for%20Adolescents%20with%20Obesity&rft.jtitle=NEW%20ENGLAND%20JOURNAL%20OF%20MEDICINE&rft.au=Kelly,%20Aaron%20S&rft.date=2020-05-28&rft.volume=382&rft.issue=22&rft.spage=2117&rft.epage=2128&rft.pages=2117-2128&rft.issn=0028-4793&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E20_500_12942_755274%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true